13F Holdings
中文EN

XNCR Xencor Inc

Pharmaceutical Preparations · Nasdaq · SEC CIK 1326732 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY19.8%
TTM net income YoY15.1%
TTM EPS YoY9.8%
Revenue 3-yr CAGR11.3%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-72.7%
Net margin-58.8%
FCF margin-88.0%
EBITDA margin-67.9%

Returns

ROE-19.9%
ROA-14.4%
ROIC (approx.)-17.4%
Asset turnover0.24x

Leverage & solvency

Liabilities / assets27.3%
Debt / equity0.17x
Current ratio6.54x
Interest coverage-6.19x

Cash quality & payout

Operating cash flow / net income1.46x
Accruals ratio6.6%
Payout ratio—
Capex / revenue2.0%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$125.58M$110.49M$174.62M$164.58M$275.11M
R&D expense$239.43M$227.69M$253.60M$199.56M$192.51M
SG&A expense$63.64M$61.22M$53.38M$47.49M$38.84M
Operating income-$177.50M-$178.41M-$132.36M-$82.47M$43.77M
Interest expense$31.93M$36.64M$6.18M$13,000$13,000
Pretax income-$89.63M-$234.92M-$119.63M-$54.51M$82.63M
Income tax$2.50M$1.62M$13.66M$673,000$0
Net income-$91.92M-$232.62M-$133.13M-$55.18M$82.63M
EBITDA-$166.99M-$166.30M-$120.86M-$73.67M$51.26M
EPS (basic)-1.24-3.58-2.20-0.931.42
EPS (diluted)-1.24-3.58-2.20-0.931.37
Weighted avg. shares (diluted)74.24M65.04M60.50M59.65M60.50M
Banking
Net interest income—$31.93M$19.33M$4.83M$849,000
Balance sheet
Cash & equivalents$54.07M$41.26M$54.17M$53.94M$143.48M
Receivables$29.30M$60.85M$23.74M$29.00M$66.38M
Current assets$599.82M$577.60M$635.60M$675.34M$424.37M
PP&E, net$53.31M$59.80M$66.12M$59.18M$28.24M
Intangibles$8.38M$18.48M$18.66M$18.50M$16.49M
Total assets$875.50M$951.95M$965.13M$846.27M$838.21M
Current liabilities$95.91M$87.43M$73.92M$63.84M$70.74M
Short-term debt$43.27M$48.45M$27.71M$0—
Long-term debt$76.48M$115.16M$161.77M$0—
Total debt$119.75M$163.61M$189.48M$0—
Total liabilities$239.91M$277.92M$303.05M$118.77M$104.71M
Shareholders' equity$635.59M$677.61M$661.75M$727.50M$733.50M
Net debt$65.68M$122.34M$135.31M-$53.94M—
Shares outstanding71.87M70.26M61.00M60.00M59.36M
Cash flow statement
Operating cash flow-$135.12M-$202.19M-$77.93M$24.48M-$16.85M
Capital expenditure$3.15M$6.10M$18.45M$38.49M$13.30M
Free cash flow-$138.27M-$208.28M-$96.37M-$14.01M-$30.15M
Investing cash flow$139.99M-$7.87M-$111.06M-$119.72M-$46.25M
Financing cash flow$8.23M$197.15M$189.22M$5.70M$43.04M
Depreciation & amortization$10.51M$12.11M$11.50M$8.80M$7.49M
Stock-based compensation$43.23M$53.28M$53.76M$48.91M$36.98M

Free plan shows the latest 5 periods; Pro shows all 14 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.